Bisantrene

Race Oncology Ltd submitted an ethics and regulatory package for a Phase 1 trial of RC220 bisantrene at Southside Cancer Care Centre, with first patient recruitment anticipated in Q1 2025. The trial aims to assess RC220's safety and tolerability in combination with doxorubicin, with potential to reduce side effects and improve outcomes. Additional sites in Australia, Hong Kong, and South Korea are planned, aiming for 10 active sites. The trial will use a Bayesian statistical design and proceed in two stages, with Stage 2 planned to begin upon HREC approval.